Anti-angiogenesis

Abstract

Antiangiogenesis was proposed as a cancer therapy over 20 years ago and the list of compounds reported to possess antiangiogenic activity is extensive. Inhibitors are grouped as specific and non-specific, depending on whether they inhibit proliferation and/or migration of endothelial cells only or are also cytotoxic for tumor cells. The antiangiogenic therapy is an important tool for the treatment of hematological malignancies. Strategies that target both the stromal and tumor compartments, such as combining traditional cytotoxic chemotherapy with antiangiogenic agents, may have an impact on drug resistance and improve the therapeutic response.